People
Raremark, the leading patient-data platform in rare disease, is pleased to announce additions to its executive team to speed the company’s pursuit of more treatments for rare medical conditions.
Lyfebulb and Helsinn Announce 11 Finalists for the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award
As the J.P. Morgan Healthcare Conference winds down for 2020, one of the big topics was the general lack of big deals. Still, there were some general trends and for today, some news.
Pharma companies add new members to executive ranks and boards of directors.
The first of the Insys Therapeutics executives found guilty of violating the Racketeer Influenced and Corrupt Organizations Act in May 2019 has been sentenced.
The company, which has secured enormous investments over the past few years, is inching closer to being a commercial company in developing personalized therapies for a wide range of diseases, including cancer.
The two companies joined their consumer health businesses in order to give the parent companies more maneuverability to focus on the pharmaceuticals.
In a filing this week, the government said that tens of thousands of patients received “unreliable blood tests,” which deprived them of money and placed their health at risk.
The company’s chief executive officer, Ludwig Hantson, admits it’s a longshot.
In 2016, Soon-Shiong announced the Cancer Moonshot and set a 2020 deadline, claiming he would transform the war on cancer.
PRESS RELEASES